JOHAN R. BOELAERT, M.D.; PHILIPPE L. VERGAUWE, M.D.; JOZEF M. VANDEPITTE, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: Veis and associates (1) reported fatal rhinocerebral mucormycosis in two nondiabetic dialysis patients receiving deferoxamine. Fatal mucormycosis developed in two of our patients on dialysis for 10 and 14 years, respectively, and receiving deferoxamine for 4 to 7 months, respectively. Several analogous cases have been reported (2). Because most of these patients were receiving deferoxamine, which is a siderophore, deferoxamine may serve as a growth factor for this fungus.
Deferoxamine has also been incriminated in the pathogenesis of infections with Yersinia enterocolitica. We reported 11 cases of bacteremia with Yersinia (Y. enterocolitica in 10 cases and Y.
BOELAERT JR, VERGAUWE PL, VANDEPITTE JM. Mucormycosis Infection in Dialysis Patients. Ann Intern Med. ;107:782–783. doi: 10.7326/0003-4819-107-5-782_2
Download citation file:
Published: Ann Intern Med. 1987;107(5):782-783.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use